@article{3f691a4a2920436dbb225458a83f9cc7,
title = "Elective genomic testing: Practice resource of the National Society of Genetic Counselors",
abstract = "Genetic counseling for patients who are pursuing genetic testing in the absence of a medical indication, referred to as elective genomic testing (EGT), is becoming more common. This type of testing has the potential to detect genetic conditions before there is a significant health impact permitting earlier management and/or treatment. Pre- and post-test counseling for EGT is similar to indication-based genetic testing. Both require a complete family and medical history when ordering a test or interpreting a result. However, EGT counseling has some special considerations including greater uncertainties around penetrance and clinical utility and a lack of published guidelines. While certain considerations in the selection of a high-quality genetic testing laboratory are universal, there are some considerations that are unique to the selection of a laboratory performing EGT. This practice resource intends to provide guidance for genetic counselors and other healthcare providers caring for adults seeking pre- or post-test counseling for EGT. Genetic counselors and other genetics trained healthcare providers are the ideal medical professionals to supply accurate information to individuals seeking counseling about EGT enabling them to make informed decisions about testing and follow-up.",
keywords = "direct-to-consumer genetic testing (DTC), genetic counseling, genetic testing, population screening, predictive genetic testing",
author = "Blout Zawatsky, {Carrie L.} and David Bick and Louise Bier and Birgit Funke and Matthew Lebo and Lewis, {Katie L.} and Ekaterina Orlova and Emily Qian and Lauren Ryan and Schwartz, {Marci L.B.} and Soper, {Emily R.}",
note = "Funding Information: Carrie Blout Zawatsky, Louise Bier, Katie Lewis, Marci Schwartz, and Emily Soper declare that they had no conflict of interest during the development of this practice resource. Lauren Ryan is a full‐time employee of GRAIL, LLC, had a Tier 1 COI as a previous full‐time employee of Color Genomics at the beginning of development (employment ended March 2021), and owns stock in GRAIL, LCC and Color Health, Inc. Ekaterina Orlova had a Tier 2 COI for contract work with Ariel Precision Medicine at the beginning of development, but no COI by Nov 2021. Emily Qian had a Tier 1 COI as a previous full‐time employee of Veritas Genetics at the beginning of development (employment ended December 2019), but no COI by December 2020. David Bick has Tier 2 COI for consultancy work with HudsonAlpha Clinical Services Lab LLC, iRepertoire Molecular Lab, and Northwestern Mutual Life Insurance Company and was employed by Smith Family Clinic for Genomic Medicine until October 2021. Matthew Lebo has Tier 1 COI as a full‐time employee of a not‐for‐profit molecular genetic testing laboratory (Laboratory for Molecular Medicine within Mass General Brigham). Birgit Funke had a Tier 1 COI for the majority of the development as a full‐time employee for Veritas Genetics until December 2019 and Sema4 from March 2020 until present. KLL received salary support from the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health (NIH grant HG200387‐08). Publisher Copyright: {\textcopyright} 2023 National Society of Genetic Counselors.",
year = "2023",
month = apr,
doi = "10.1002/jgc4.1654",
language = "English",
volume = "32",
pages = "281--299",
journal = "Journal of Genetic Counseling",
issn = "1059-7700",
publisher = "Kluwer Academic/Human Sciences Press Inc.",
number = "2",
}